American Bio Medica

American Bio Medica FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of American Bio Medica (ABMC) as of Nov 20, 2026 is 54.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 145.36 % — a change of -62.53% (lower).

FCF Conversion

54.47 %

YoY

-62.53%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of American Bio Medica is 2022 54.47 % . FCF Conversion Rate (FCF/EBITDA) of American Bio Medica was 2021 145.36 % . It decreases by -62.53% lower compared to the previous year.

The American Bio Medica FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
-62.76 USD
Jan 1, 2016
-61.16 USD
Jan 1, 2017
-21.47 USD
Jan 1, 2018
23.54 USD
Jan 1, 2019
-8.52 USD
Jan 1, 2020
61.18 USD
Jan 1, 2021
145.36 USD
Jan 1, 2022
54.47 USD
The American Bio Medica FCF Conversion history
YEARFCF ConversionYoY
54.47 %-62.53%
145.36 %+137.58%
61.18 %-818.35%
-8.52 %-136.18%
23.54 %-209.66%
-21.47 %-64.90%
-61.16 %-2.55%
-62.76 %+1,237.12%
-4.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Bio Medica Stock analysis

What does American Bio Medica do? American Bio Medica Corp is a US-based company specializing in the development and manufacture of drug testing devices and diagnostic products. The company was founded in 1986 and is headquartered in Kinderhook, New York. Its business model involves developing and producing drug testing devices and diagnostic products used by government agencies, companies, and private customers worldwide. The company also operates a laboratory that conducts diagnostic tests for third parties. Its five business areas include drug tests, medication safety, diagnostics, biometrics, and forensics. The company's products include urine, saliva, and sweat drug tests, as well as medical devices to prevent prescription drug abuse and diagnostic products for various diseases. It also offers biometric instruments and systems for person identification and forensic products for crime investigation. American Bio Medica Corp has been publicly traded since 1992 and has received several awards for its products and innovations. The company is committed to research and development, quality assurance, and accuracy in its products. Overall, it is a leading company in the field of drug testing devices and diagnostic products and is expected to continue to evolve in the future. American Bio Medica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Bio Medica stock

FCF Conversion Rate (FCF/EBITDA) of American Bio Medica is 54.47 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of American Bio Medica changed from 145.36 % to 54.47 %, representing a -62.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) American Bio Medica since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s American Bio Medica with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — American Bio Medica

All Key Metrics — American Bio Medica